- South Korea
- /
- Medical Equipment
- /
- KOSDAQ:A048870
Earnings Not Telling The Story For Synergy Innovation Co., Ltd. (KOSDAQ:048870) After Shares Rise 50%
The Synergy Innovation Co., Ltd. (KOSDAQ:048870) share price has done very well over the last month, posting an excellent gain of 50%. The last 30 days bring the annual gain to a very sharp 47%.
Following the firm bounce in price, Synergy Innovation may be sending very bearish signals at the moment with a price-to-earnings (or "P/E") ratio of 32x, since almost half of all companies in Korea have P/E ratios under 11x and even P/E's lower than 6x are not unusual. However, the P/E might be quite high for a reason and it requires further investigation to determine if it's justified.
We've discovered 2 warning signs about Synergy Innovation. View them for free.Recent times have been quite advantageous for Synergy Innovation as its earnings have been rising very briskly. It seems that many are expecting the strong earnings performance to beat most other companies over the coming period, which has increased investors’ willingness to pay up for the stock. You'd really hope so, otherwise you're paying a pretty hefty price for no particular reason.
Check out our latest analysis for Synergy Innovation
How Is Synergy Innovation's Growth Trending?
There's an inherent assumption that a company should far outperform the market for P/E ratios like Synergy Innovation's to be considered reasonable.
Taking a look back first, we see that the company grew earnings per share by an impressive 330% last year. Still, EPS has barely risen at all from three years ago in total, which is not ideal. Therefore, it's fair to say that earnings growth has been inconsistent recently for the company.
Comparing that to the market, which is predicted to deliver 21% growth in the next 12 months, the company's momentum is weaker based on recent medium-term annualised earnings results.
In light of this, it's alarming that Synergy Innovation's P/E sits above the majority of other companies. It seems most investors are ignoring the fairly limited recent growth rates and are hoping for a turnaround in the company's business prospects. Only the boldest would assume these prices are sustainable as a continuation of recent earnings trends is likely to weigh heavily on the share price eventually.
The Key Takeaway
Shares in Synergy Innovation have built up some good momentum lately, which has really inflated its P/E. While the price-to-earnings ratio shouldn't be the defining factor in whether you buy a stock or not, it's quite a capable barometer of earnings expectations.
We've established that Synergy Innovation currently trades on a much higher than expected P/E since its recent three-year growth is lower than the wider market forecast. Right now we are increasingly uncomfortable with the high P/E as this earnings performance isn't likely to support such positive sentiment for long. If recent medium-term earnings trends continue, it will place shareholders' investments at significant risk and potential investors in danger of paying an excessive premium.
Plus, you should also learn about these 2 warning signs we've spotted with Synergy Innovation.
Of course, you might also be able to find a better stock than Synergy Innovation. So you may wish to see this free collection of other companies that have reasonable P/E ratios and have grown earnings strongly.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About KOSDAQ:A048870
Synergy Innovation
Engages in the research and development, and investment of generic and new drugs, medical devices, and health functional foods in South Korea.
Flawless balance sheet with questionable track record.
Similar Companies
Market Insights
Weekly Picks

An Undervalued 3.3Moz Gold Project in Canada

GameStop will ace the financial crisis wave with its strategic Bitcoin investment and cash reserves
The First Real Lidar Winner

The Most Wonderful Monopoly in the Most Dangerous Neighbourhood on Earth
Recently Updated Narratives

A Case for Guanajuato Silver (TSXV:GSVR) to reach (low end) CAD$4 (high end) CAD$18 by 2031
Bambuser is today the only listed company in Europe that simultaneously possesses an 85% gross margin, proprietary AI infrastructure for the

Pre Commercialization optimism
Popular Narratives
SoFi Technologies: The Apex Aggregator and the Infrastructure of the Modern Financial System

Everyone's Terrified Microsoft Will Keep Spending. I'm Terrified They'll Stop.
